keyword
MENU ▼
Read by QxMD icon Read
search

statin in acute coronary syndrome

keyword
https://www.readbyqxmd.com/read/28104770/decline-in-cardiovascular-mortality-possible-causes-and-implications
#1
REVIEW
George A Mensah, Gina S Wei, Paul D Sorlie, Lawrence J Fine, Yves Rosenberg, Peter G Kaufmann, Michael E Mussolino, Lucy L Hsu, Ebyan Addou, Michael M Engelgau, David Gordon
If the control of infectious diseases was the public health success story of the first half of the 20th century, then the decline in mortality from coronary heart disease and stroke has been the success story of the century's past 4 decades. The early phase of this decline in coronary heart disease and stroke was unexpected and controversial when first reported in the mid-1970s, having followed 60 years of gradual increase as the US population aged. However, in 1978, the participants in a conference convened by the National Heart, Lung, and Blood Institute concluded that a significant recent downtick in coronary heart disease and stroke mortality rates had definitely occurred, at least in the US Since 1978, a sharp decline in mortality rates from coronary heart disease and stroke has become unmistakable throughout the industrialized world, with age-adjusted mortality rates having declined to about one third of their 1960s baseline by 2000...
January 20, 2017: Circulation Research
https://www.readbyqxmd.com/read/28099219/a-review-of-the-clinical-utility-of-intravascular-ultrasound-ivus-and-optical-coherence-tomography-oct-in-the-assessment-and-treatment-of-coronary-artery-disease
#2
Stephen Daniel Matthews, William H Frishman
Coronary artery disease (CAD) remains one of the leading causes of morbidity and mortality in the United States. As a medical society, we continue to search for ways to better treat CAD and prevent acute coronary syndrome (ACS). As it stands, only statins and anti-platelets agents have been proven to significantly reduce the occurrence of ACS. A histopathological understanding of the pathogenesis of ACS has provided insight into the importance of plaque morphology. Therefore, it has been proposed that increasing the ability to detect true vulnerable, "at-risk" lesions, would foster the use of percutaneous coronary intervention as a means for the prevention of ACS...
January 11, 2017: Cardiology in Review
https://www.readbyqxmd.com/read/28097904/estimated-burden-of-cardiovascular-disease-and-value-based-price-range-for-evolocumab-in-a-high-risk-secondary-prevention-population-in-the-us-payer-context
#3
Peter P Toth, Mark Danese, Guillermo Villa, Yi Qian, Anne Beaubrun, Armando Lira, Jeroen P Jansen
AIM: To estimate real-world cardiovascular disease (CVD) burden and value-based price range of evolocumab for a US-context, high-risk, secondary-prevention population. MATERIALS AND METHODS: Burden of CVD was assessed using the UK-based Clinical Practice Research Datalink (CPRD) in order to capture complete CV burden including CV mortality. Patients on standard of care (SOC; high-intensity statins) in CPRD were selected based on eligibility criteria of FOURIER, a phase 3 CV outcomes trial of evolocumab, and categorized into 4 cohorts: high-risk prevalent atherosclerotic CVD (ASCVD) cohort (N = 1448), acute coronary syndrome (ACS) (N = 602), ischemic stroke (IS) (N = 151), and heart failure (HF) (N = 291) incident cohorts...
January 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28092990/in-hospital-statin-underutilization-among-high-risk-patients-delayed-uptake-of-the-2013-cholesterol-guidelines-in-a-u-s-cohort
#4
Subeer K Wadia, Mark Belkin, Kelsey Chow, Jonathan Nattiv, Andrew Appis, Steven B Feinstein, Kim Allan Williams
OBJECTIVES: Clinician utilization of the 2013 cholesterol lowering guidelines remains variable and unknown. We sought to examine statin prescribing patterns and compare rates among specialists who treat high-risk cardiovascular patients admitted to the hospital. METHODS: We retrospectively (via chart review) examined four specialty groups: (i) Cardiology, (ii) Cardiovascular or Vascular (CV) Surgery, (iii) Neurology, and (iv) Internal Medicine. Adult patients were included based on a discharge diagnosis of acute coronary syndrome, coronary artery bypass graft surgery, carotid endarterectomy, acute ischemic stroke, transient ischemic attack, or high-risk chest pain...
January 17, 2017: Hospital Practice (Minneapolis)
https://www.readbyqxmd.com/read/28077384/predictors-of-nonuse-of-a-high-potency-statin-after-an-acute-coronary-syndrome-insights-from-the-stabilization-of-plaques-using-darapladib-thrombolysis-in-myocardial-infarction-52-solid-timi-52-trial
#5
Alon Eisen, Christopher P Cannon, Eugene Braunwald, Dylan L Steen, Jing Zhou, Erica L Goodrich, KyungAh Im, Anthony J Dalby, Jindrich Spinar, Shruti Daga, Mary Ann Lukas, Michelle L O'Donoghue
BACKGROUND: High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. METHODS AND RESULTS: The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician...
January 11, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28072688/factors-associated-with-unattained-ldl-cholesterol-goals-in-chinese-patients-with-acute-coronary-syndrome-one-year-after-percutaneous-coronary-intervention
#6
Wenduo Zhang, Fusui Ji, Xue Yu, Xinyue Wang
Reducing low-density lipoprotein cholesterol (LDL-C) to target ≤1.81 mmol/L is a common therapeutic goal after acute coronary syndrome (ACS). This study aimed to examine the factors associated with reaching or not this LDL-C target after 1 year of optimal statin therapy postpercutaneous coronary intervention (PCI). This was a retrospective study of 633 consecutive prospectively enrolled patients with ACS treated between January 2011 and December 2012 at the Beijing Hospital (China). All patients were treated with PCI and statins for 1 year...
January 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28068529/impact-of-high-dose-statins-on-vitamin-d-levels-and-platelet-function-in-patients-with-coronary-artery-disease
#7
Monica Verdoia, Patrizia Pergolini, Roberta Rolla, Matteo Nardin, Alon Schaffer, Lucia Barbieri, Veronica Daffara, Paolo Marino, Giorgio Bellomo, Harry Suryapranata, Giuseppe De Luca
BACKGROUND: Statins represent a pivotal treatment in coronary artery disease, offering a reduction in cardiovascular risk even beyond their lipid-lowering action. However, the mechanism of these "pleiotropic" benefits of statins is poorly understood. Vitamin D has been suggested as a potential mediator of the anti-inflammatory, anti-thrombotic and vascular protecting effects of statins. Aim of present study was to assess the impact of a high-intensity statin therapy on vitamin D levels and platelet function in patients with coronary artery disease...
December 28, 2016: Thrombosis Research
https://www.readbyqxmd.com/read/28058865/impact-of-pharmacist-intervention-to-increase-compliance-with-guideline-directed-statin-therapy-during-an-acute-coronary-syndrome-hospitalization
#8
Robert K Tunney, Daniel C Johnson, Li Wang, Zachary L Cox
BACKGROUND: Despite evidence on poor adherence to guideline-directed statin therapy (GDST) following an acute coronary syndrome (ACS), little information has been published on pharmacist-led statin pilot programs for secondary prevention. OBJECTIVE: We sought to evaluate the impact of a pharmacist intervention (PI) on GDST during an ACS hospitalization. METHODS: A historical control (HC) group consisting of 125 ACS hospitalizations was retrospectively identified, with prospective data of 113 patients captured over 6 months in the PI group...
January 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28049984/clinical-outcomes-in-diabetic-patients-who-underwent-percutaneous-coronary-intervention-during-the-plain-old-balloon-angioplasty-poba-bare-metal-stents-bms-and-drug-eluting-stents-des-eras-from-1984-to-2010
#9
Ryo Naito, Katsumi Miyauchi, Hirokazu Konishi, Shuta Tsuboi, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Hiroshi Tamura, Shinya Okazaki, Kikuo Isoda, Hiroyuki Daida
Objective Diabetes is a negative predictor in coronary artery disease patients. Since the introduction of percutaneous coronary intervention (PCI), PCI has evolved through technological advances in devices, improvements in operators' techniques and the establishment of effective therapeutic protocols. The aim of this study is to examine the changes in the clinical outcomes following PCI in patients with diabetes. Methods We compared the clinical outcomes in patients with diabetes following PCI from 1984 to 2010 at Juntendo University over three eras (plain old balloon angioplasty (POBA)-, bare metal stents (BMS)- and drug-eluting stents (DES)-eras)...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28042404/in-hospital-and-one-year-clinical-outcome-of-percutaneous-coronary-intervention-in-a-tertiary-hospital-in-oman-oman-pci-registry
#10
Prashanth Panduranga, Majdah Al-Rashidi, Fatma Al-Hajri
OBJECTIVES: The aim of the study was to investigate the in-hospital and one-year clinical outcome of patients treated with percutaneous coronary intervention (PCI) in a tertiary hospital in Oman. METHODS: We conducted a retrospective, single-center, observational study looking at patients > 18 years old who underwent a PCI from 1 January to 31 December 2013. The primary end point was the occurrence of a major adverse cardiovascular event (MACE), defined as death, any myocardial infarction (MI), cerebrovascular accident (CVA), and target vessel revascularization (TVR) with either repeat PCI or coronary artery bypass surgery (CABG)...
January 2017: Oman Medical Journal
https://www.readbyqxmd.com/read/28034517/impact-of-paradoxical-decrease-in-high-density-lipoprotein-cholesterol-levels-after-statin-therapy-on-major-adverse-cardiovascular-events-in-patients-with-stable-angina-pectoris
#11
Kenshi Hirayama, Tomoyuki Ota, Kazuhiro Harada, Yohei Shibata, Yosuke Tatami, Shingo Harata, Kazuhiro Kawashima, Ayako Kunimura, Yusaku Shimbo, Yohei Takayama, Toshiki Kawamiya, Dai Yamamoto, Naohiro Osugi, Susumu Suzuki, Hideki Ishii, Toyoaki Murohara
PURPOSE: Statin therapy usually increases HDL-C levels. However, a paradoxical decrease in HDL-C levels after statin therapy is often seen in clinical settings. The relationship between a paradoxical decrease in HDL-C levels after statin therapy and adverse cardiovascular events in patients with stable angina pectoris (SAP) is not well understood. The purpose of this study was to analyze the relationship between paradoxical HDL-C decreases after statin therapy and major adverse cardiovascular events (MACEs) in patients undergoing percutaneous coronary intervention (PCI) for SAP...
December 26, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/28026031/patterns-and-predictors-of-lipid-lowering-therapy-in-patients-with-atherosclerotic-cardiovascular-disease-and-or-diabetes-mellitus-in-2014-insights-from-a-large-us-managed-care-population
#12
Dylan L Steen, Irfan Khan, Laura Becker, JoAnne M Foody, Katherine Gorcyca, Robert J Sanchez, Robert P Giugliano
BACKGROUND: Lowering low-density lipoprotein cholesterol with statins reduces risk of cardiovascular events. We examined patterns and predictors of filled prescriptions for lipid-lowering therapy (LLT) in subgroups of patients with atherosclerotic cardiovascular disease (ASCVD) and/or diabetes mellitus (DM). HYPOTHESIS: Statin treatment remains underutilized across subgroups of high CV risk patients. METHODS: Patients in the Optum Research Database with these criteria were included: age ≥20 years, 2 years continuous enrollment, and ASCVD and/or DM...
December 27, 2016: Clinical Cardiology
https://www.readbyqxmd.com/read/27982163/mortality-reduction-with-use-of-oral-beta-blockers-in-patients-with-acute-coronary-syndrome
#13
Alexandre de Matos Soeiro, Pedro Gabriel Melo de Barros E Silva, Eduardo Alberto de Castro Roque, Aline Siqueira Bossa, Cindel Nogueira Zullino, Sheila Aparecida Simões, Mariana Yumi Okada, Tatiana de Carvalho Andreucci Torres Leal, Maria Carolina Feres de Almeida Soeiro, Carlos V Serrano, Múcio Tavares Oliveira
OBJECTIVES: Recent studies have revealed a relationship between beta-blocker use and worse prognosis in acute coronary syndrome, mainly due to a higher incidence of cardiogenic shock. However, the relevance of this relationship in the reperfusion era is unknown. The aim of this study was to analyze the outcomes of patients with acute coronary syndrome that started oral beta-blockers within the first 24 hours of hospital admission (group I) compared to patients who did not use oral beta-blockers in this timeframe (group II)...
November 1, 2016: Clinics
https://www.readbyqxmd.com/read/27979047/statin-therapy-and-low-density-lipoprotein-cholesterol-reduction-in-hiv-infected-individuals-after-acute-coronary-syndrome-results-from-the-pacs-hiv-lipids-substudy
#14
Franck Boccara, Joe Miantezila Basilua, Murielle Mary-Krause, Sylvie Lang, Emmanuel Teiger, Philippe Gabriel Steg, Christian Funck-Brentano, Pierre-Marie Girard, Dominique Costagliola, Ariel Cohen, Marguerite Guiguet
: Knowledge about lipid interventions in secondary prevention in HIV-infected individuals is limited; studies are sparse. METHODS: A prospective observational multicenter study enrolled 282 patients on statin 1 month after first acute coronary syndrome (ACS) (95 HIV-infected individuals, 187 HIV-uninfected). Data on fasting lipids (total cholesterol [TC], low-density lipoprotein cholesterol, high-density lipoprotein cholesterol [HDL-C], non-HDL-C, triglycerides, TC/HDL-C ratio) were collected over 3 years...
January 2017: American Heart Journal
https://www.readbyqxmd.com/read/27931556/non-physician-health-workers-for-improving-adherence-to-medications-and-healthy-lifestyle-following-acute-coronary-syndrome-24-month-follow-up-study
#15
Krishna Kumar Sharma, Rajeev Gupta, Mukul Mathur, Vishnu Natani, Sailesh Lodha, Sanjeeb Roy, Denis Xavier
OBJECTIVE: To evaluate usefulness of non-physician health workers (NPHW) to improve adherence to medications and lifestyles following acute coronary syndrome (ACS). METHODS: We randomized 100 patients at hospital discharge following ACS to NPHW intervention (n=50) or standard care (n=50) in an open label study. NPHW was trained for interventions to improve adherence to medicines - antiplatelets, β-blockers, renin-angiotensin system (RAS) blockers and statins and healthy lifestyles...
November 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27931543/efficacy-and-safety-of-the-intensive-dose-of-rosuvastatin-40mg-day-in-patients-with-acute-coronary-syndrome-and-at-high-risk-of-cardiovascular-disease-rosuvees-2
#16
Chetan P Shah, Bhaskar P Shah, Sameer I Dani, B B Channa, S S Lakshmanan, N C Krishnamani, Ashwani Mehta, P Moorthy
BACKGROUND: Randomized clinical trials have established the benefits of statin therapy in acute coronary syndromes (ACS) via their pleiotropic effects. AIM OF THE STUDY: This was a 12-week, open-label, multicenter, postmarketing observational study evaluating the efficacy and safety of rosuvastatin 40 mg/day in very high-risk or high-risk Indian patients according to NCEP ATP III guidelines. METHODOLOGY: One hundred and sixty two patients (age: 30 to 69 years) with evidence of coronary artery disease, hospitalized with chest pain with/without electrocardiogram changes and with non-ST segment elevation ACS and ST segment elevation ACS who received optimal reperfusion therapy were enrolled...
November 2016: Indian Heart Journal
https://www.readbyqxmd.com/read/27927063/inflammation-and-beyond-new-directions-and-emerging-drugs-for-treating-atherosclerosis
#17
Marie-Jeanne Bertrand, Jean-Claude Tardif
Cardiovascular (CV) atherosclerotic disease remains the leading cause of morbidity and mortality worldwide, despite the advances in contemporary therapies. Inflammation is an important process in atherosclerosis, leading to plaque rupture and acute coronary syndrome. Although statin therapy has substantially reduced CV events in primary and secondary prevention, many treated patients will have recurrent adverse CV events despite the standard of care. Thus, drug development aiming to target inflammatory pathways seems a promising avenue for novel therapies in atherosclerosis...
December 22, 2016: Expert Opinion on Emerging Drugs
https://www.readbyqxmd.com/read/27899853/four-statin-benefit-groups-defined-by-the-2013-acc-aha-new-cholesterol-guideline-are-characterized-by-increased-plasma-level-of-electronegative-low-density-lipoprotein
#18
Chih-Sheng Chu, Liang-Yin Ke, Hua-Chen Chan, Hsiu-Chua Chan, Chih-Chieh Chen, Kai-Hung Cheng, Hsiang-Chun Lee, Hsuan-Fu Kuo, Ching-Tang Chang, Kuan-Cheng Chang, Sheng-Hsiung Sheu, Chu-Huang Chen, Wen-Ter Lai
BACKGROUND: Significantly higher cytotoxic and thrombogenic human electronegative low-density lipoprotein (LDL), or L5, has been found in patients with stable coronary artery disease and acute coronary syndrome. We hypothesized that the statin-benefit groups (SBGs) defined by the new cholesterol guideline were of higher electronegative L5. METHODS: In total, 62 hyperlipidemia patients (mean age 59.4 ± 10.5, M/F 40/22) were retrospectively divided into SBGs (n = 44) and N-SBGs (n = 18)...
November 2016: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/27895696/efficacy-of-danlou-tablet-in-patients-with-non-st-elevation-acute-coronary-syndrome-undergoing-percutaneous-coronary-intervention-results-from-a-multicentre-placebo-controlled-randomized-trial
#19
Lei Wang, Xujie Zhao, Shuai Mao, Shaonan Liu, Xinfeng Guo, Liheng Guo, Tinghai Du, Haiyu Yang, Fuhai Zhao, Keng Wu, Hongliang Cong, Yang Wu, Phillip C Yang, Keji Chen, Minzhou Zhang
This study seeks to investigate potential cardioprotection of Danlou Tablets in patients undergoing PCI with non-ST elevation acute coronary syndrome (NSTE-ACS). 219 patients with NSTE-ACS were randomised to Danlou Tablet pretreatment (n = 109) or placebo (n = 110). No patients received statins prior to PCI and all patients were given atorvastatin (10 mg/day) after procedure. The main endpoint was the composite incidence of major adverse cardiac events (MACEs) within 30 days after PCI. The proportion of patients with elevated levels of cTn I>5 × 99% of upper reference limit was significantly lower in the Danlou Tablet group at 8 h (22...
2016: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/27894787/safety-and-efficacy-of-liraglutide-treatment-in-japanese-type-2-diabetes-patients-after-acute-myocardial-infarction-a-non-randomized-interventional-pilot-trial
#20
Masataka Kajiwara, Atsushi Tanaka, Tomohiro Kawasaki, Koichi Nakao, Tomohiro Sakamoto, Shigeru Toyoda, Teruo Inoue, Nobuhiko Koga, Koichi Node
BACKGROUND: Glucagon-like peptide 1 analogs are expected to exert a cardio-protective action due to their effective glucose-lowering action and favorable potency on multifactorial metabolic pathways. However, the safety and tolerability of liraglutide treatment after a recent acute coronary syndrome (ACS) in Japanese patients with type 2 diabetes mellitus (T2DM) have yet to be fully established. METHODS: A total of eight T2DM patients were recruited within 2 weeks after the onset of a ST-elevation myocardial infarction (STEMI) followed by successful percutaneous coronary intervention (PCI)...
November 25, 2016: Journal of Cardiology
keyword
keyword
45397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"